Marqibo vincristine regulatory update

FDA granted accelerated approval to an NDA from Talon for Marqibo vincristine to treat Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in patients with >=2 relapses

Read the full 259 word article

How to gain access

Continue reading with a
two-week free trial.